Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib + Ofatumumab in R/R CLL
NCT01532700Phase 2Completed
- Sponsor
- University Health Network
- Start
- Feb 2012
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in chronic lymphocytic leukemia (CLL), sponsored by University Health Network. Primary endpoint: Overall Response Rate at 36 months. Started Feb 2012; status: completed.
02
Drugs
afuresertib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01532700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532700.